Hs Koops

Acute effects of cis-diamminedichloroplatinum (CDDP) on renal function

SummaryTen previously untreated patients with metastatic non-seminomatous testicular carcinoma received cis-diamminechloroplatinum (CDDP). Renal function studies were performed before and following the first CDDP infusion. A decrease in effective renal plasma flow (ERPF) and an increase in filtration fraction (FF) was found in all patients. These findings suggest primary changes in renal hemodynamics during CDDP infusion.

Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities.

Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumours of the extremities

INFLUENCE OF PLATINUM-INDUCED RENAL TOXICITY ON BLEOMYCIN-INDUCED PULMONARY TOXICITY IN PATIENTS WITH DISSEMINATED TESTICULAR-CARCINOMA

Pulmonary function tests, including T1CO, and renal function tests were performed and GFR and ERPF measured in 18 patients with disseminated testicular non-seminoma before and after remission induction according to the Einhorn regimen. We found a significant positive correlation between delta GFR and delta T1CO (p less than 0.05). No significance could be demonstrated between delta ERPF and delta T1CO. It is concluded that caution should be exercised in administrating bleomycin to patients with severely impaired renal function.

Changes in pulmonary function during and after bleomycin treatment in patients with testicular carcinoma

SummaryPulmonary function tests, including spirometry, transfer factor of the lungs for carbon monoxide (TlCO), and the two components of TlCO, the diffusing capacity of the alveolocapillary membrane (Dm) and pulmonary capillary blood volume (Vc), were carried out in a group of patients with testicular carcinoma during and after treatment with the Einhorn regimen. The lung function parameters of patients who developed bleomycin-induced pneumonitis were compared with those recorded in a group of patients who did not develop this syndrome.We suggest that bleomycin-induced damage to the pulmonary capillary vasculature can be monitored by measuring Vc and that ensuing fibrosis can be measured by recording Dm. The decrease in Dm is probably compensated for by an increase in Vc, leading to a smaller change in TlCO.

SERUM LACTATE-DEHYDROGENASE ISOENZYME-1 ACTIVITY IN PATIENTS WITH TESTICULAR GERM-CELL TUMORS CORRELATES WITH THE TOTAL NUMBER OF COPIES OF THE SHORT ARM OF CHROMOSOME-12 IN THE TUMOR

SummaryThe aim of our study was to assess the relationship between the serum lactate dehydrogenase isoenzyme 1 (S-LDH-1) activity in patients with testicular germ cell tumors and the number of copies of the short arm of chromosome 12 (12p) present in tumor. Twenty-seven adult patients with measurable tumor lesions were studied. Twenty-five had three or more copies of chromosome 12 per cell in the tumors. Nineteen had one or more copies of a specific chromosomal abnormality, an isochromosome of the short arm of chromosome 12, i(12p). Fourteen had increased S-LDH-1 levels. S-LDH-1 activity correlated significantly with the product of total tumor volume and the total number of copies of the short arm of chromosome 12 present per cell (total tumor 12p). We conclude that the total number of copies of the short arm of chromosome 12 in the tumors is most probably a factor contributing to the LDH-1 activity released from the tumors.

Development and test of an extendable endoprosthesis for bone reconstruction in the leg

A malignant bone tumour may develop in the femur of a child. In the majority of cases it will be necessary to resect the bone involved, growth plate and adjacent tissues. A modular endoprosthetic system has been developed which can be extended non-invasively to bridge the defect resulting from such a resection. Elongation is achieved by using an external magnetic field. In vitro tests with a prototype showed that the lengthening element met all requirements. Six animal experiments showed that the lengthening element also functioned in vivo.

NON-SEMINOMATOUS GERM-CELL TUMORS OF THE TESTIS - MORPHOLOGY OF RETROPERITONEAL LYMPH-NODE METASTASES AFTER CHEMOTHERAPY

Gross and histological examination of residual retroperitoneal mature teratoma revealed different findings in patients treated with PVB remission-induction chemotherapy with maintenance chemotherapy followed by an RLND 4-6 months after PVB chemotherapy (group I) as compared to patients who received PVB chemotherapy only and underwent an RLND after 4-6 weeks (group II). RLND specimens in group I predominantly contained mature teratoma with organoid differentiation, whereas the specimens in group II often consisted of small mature teratoma areas with less-differentiated structures next to large areas of fresh tumor necrosis. Our findings suggest that, either due to maintenance chemotherapy or due to a prolonged time interval between PVB remission-induction chemotherapy and RLND, mature teratoma grows and differentiates further from tissue level to organoid level.

MALIGNANT TESTICULAR GERM-CELL TUMORS IN FATHER AND SON - A REPORT ON 2 FAMILIES

Abstract Familial occurrence of malignant testicular tumors is rare. Of 374 patients we found 2 families in which father and son had a testicular tumor. In the first family the father had a teratocarcinoma, while the son was treated initially for seminoma and later for embryonal carcinoma. In the second family the father had a seminoma and the son had an embryonal carcinoma.

Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma

Eligible for treatment were patients with histologically proven disseminated malignant melanoma, who has not received previous systemic therapy, had progressive disease, and gave informed consent. Treatment consisted of courses of 3 weeks consisting of daily α-interferon-2a (Roferon, Hoffman-La Roche, The Netherlands) in a dose of 9 million units subcutaneously. In the first 3 days of the first course 3 million units were given. On the first day of each course 750 mg m −2 DTIC (Dome, The Netherlands) was given rapidly intravenously

PHASE-II STUDY OF CARBOPLATIN AND CYTOSINE-ARABINOSIDE IN PATIENTS WITH DISSEMINATED MALIGNANT-MELANOMA

SummaryTwenty-one patients with disseminated malignant melanoma were treated with a combination of carboplatin and cytosine arabinoside. Two complete and three partial remissions occurred. No complete cross-resistance was found with a regimen containing 5-(dimethyltriazeno)imidazole-4-carboxamide (DTIC) in two patients. It is suggested that this regimen might be studied further as a second-line treatment for patients who fail on DTIC-containing treatment.